MUMBAI, India, July 26, 2024 /PRNewswire/ -- InfoComm India, India's foremost professional audiovisual (Pro AV) exhibition, is set to return to Mumbai from 3-5 September 2024 at the Jio World Convention Centre (JWCC). This year, InfoComm India 2024 expands beyond Pavilions 1 to 3 at JWCC, incorporating Jasmine Hall (at Level 3) for an even larger showcase of innovative solutions. It will showcase over 250 brands from more than 10 countries, including 35 first-time exhibitors. InfoComm India 2024 will be held. Registration is now open for professionals and businesses looking to deepen their Pro AV expertise.

Visitors can discover a plethora of solutions ranging from the latest in digital signage, to intelligent video conference systems, from artificial intelligence (AI) in LED virtual production to naked eye 3D displays, smart classroom solutions, interactive immersive projection mapping and more catering to a wide range of sectors such as education, finance, live events, urban development & smart cities. The exhibition will showcase top-tier products and innovations from renowned global brands and emerging industry players, including AERO, BENQ, Crestron, Harman, QSYS, Barco, AET, Samsung, and PeopleLink, along with WACOM, DVSI, Neotouch, Yotech Infocom, Onfinity Technologies and 30 more who are exhibiting for the first time at InfoComm India

With an expanded show floor space at Jasmine Hall, visitors can look forward to even more innovators in the Pro AV and technology space including TOYO, 4 Squares Corporation, Altex, Black Box and Wah Lee to name a few. AVIXA will also be making its presence felt at Jasmine Hall with interactive and knowledge-packed seminars hosted at its booth throughout the three days.

The 2024 InfoComm India Summit will offer over 48 free-to-attend seminars across 14 specialized tracks led by over 50 industry leaders as speakers. A glimpse of the exciting lineup of sessions includes a kick-off overview "Navigating New Horizons: Insights and Innovations Shaping India's Pro AV Landscape" led by David Labuskes, CTS, CAE, RCDD, Executive Director and CEO, AVIXA , 'Live Events & Experiential Planning' exploring Pro AV application for live events, as well as industry-focused sessions dedicated to smart cities, hospitality, and education sectors like "Future of Learning Spaces", "Securing the Future: Cybersecurity Strategies, Economics, and Risk Management", Digital Signage in the AI-age which explores real-world strategies using AI, VR, and digital platforms for immersive experiences.

"India's digital transformation is truly inspiring," said June Ko, Executive Director of InfoComm India. "We see a vibrant energy and a thirst for innovation across the country. InfoComm India 2024 is our way of bringing together the brilliant minds and passionate hearts that are shaping this new era of technology in India. We envision InfoComm India as the premier destination for the Pro AV community to exchange ideas, foster partnerships, and collectively drive the industry forward."

Connection is at the heart of InfoComm India 2024. A host of networking opportunities are designed to connect attendees with industry experts, thought leaders, and peers. They include the Breakfast Networking Hour at Luminary Lounge (Jasmine Hall) on 2 and 3 September, 9.30am to 10.00am; Flashtrack seminars and networking events at AVIXA booth; daily New Technology and Products Show Floor Tours and more.

For full details on exhibitors, products, summit agenda, registration, and sponsorship opportunities, visit www.infocomm-india.com

To access more press information of InfoComm India 2024, please visit: Digital Press Office Kit

For more information, please contact:

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/infocomm-india-2024-the-largest-edition-of-the-pro-av-exhibition-to-date---returns-3-5-september-at-jio-world-convention-centre-jwcc-mumbai-india-302207988.html

SOURCE InfoComm India

SINGAPORE, July 27, 2024 /PRNewswire/ -- Chenghe Acquisition II Co. (the "Company") today announced that, commencing on July 29, 2024, holders of the units (the "Units") sold in the Company's initial public offering may elect to separately trade the Company's Class A Ordinary Shares (the "Shares") and warrants (the "Warrants") included in the Units.

The Shares and Warrants received from the separated Units will trade on the NYSE American LLC ("NYSE") under the symbols "CHEB" and "CHEB WS", respectively. Units that are not separated will continue to trade on NYSE under the symbol "CHEB.U". No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the Units into Shares and Warrants.

The Company is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or entities. While the Company may pursue an initial target business in any industry, geography, or sector, it intends to focus its search on growing companies in Asian markets or global companies with a presence or focus in Asia.

The Units were initially offered by the Company in an underwritten offering. Cohen & Company Capital Markets acted as Lead Book-Running Manager, Seaport Global Securities acted as a Joint Book Runner for the offering, and Revere Securities LLC, Chenghe Capital Management and Webull Financial LLC acted as co-managers.

The registration statement relating to the securities became effective on June 6, 2024. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to the initial public offering and the anticipated use of the net proceeds. Words such as "will," "would," "may," "intends," "anticipates," "potential," and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the offering filed with the SEC. Copies are available on the SEC's website, www.sec.gov. The forward-looking statements contained in this press release speak only as of the date of this press release and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this press release, unless required by law.

Investor Relations Contact
Chenghe Acquisition II Co.
Maria Yuan
Email: maria.yuan@chenghecap.com

View original content:https://www.prnewswire.com/apac/news-releases/chenghe-acquisition-ii-co-announces-the-separate-trading-of-its-class-a-ordinary-shares-and-warrants-commencing-on-july-29-2024-302207807.html

SOURCE Chenghe Acquisition Co.

XINING, China, July 27, 2024 /PRNewswire/ -- vivo today held the 2024 vivo Imaging Conference in Xining, China, where it showcased vivo's latest advancements in imaging technologies. The company presented its progressive strategies surrounding three new trends in mobile imaging: imaging security, 3D imaging/XR and health imaging. In addition, the results of the VISION+ Mobile PhotoAwards 2024 were also revealed, with photographer He Jinyi's captivating work, "A Fleeting Moment in Endless Time," earning the Best Photograph of the Year.

The event saw the presence of several distinguished guests and industry partners, including Yu Meng, Vice President, Vice President of Imaging at vivo; Li Zhuo, Senior Director of Imaging Product at vivo; Sebastian Döntgen, Head of Marketing, Category Management and Sales, ZEISS Consumer Products; world-renowned color photographer Alex Webb; visual artist Duan Yueheng; director Xin Shuang; visual artist Li Xiaoliang; and Song Wen, founder of the FIRST International Film Festival.

"Over the past decade, we have steadfastly adhered to a strategy of independent and collaborative R&D, continuously advancing 'human-centric professional imaging.' We strive to be on par with the benchmarks set by professional imaging equipment, photography teams, and post-production capabilities. Going forward, vivo is committed to addressing user needs, pushing the boundaries of imaging technology in collaboration with global partners, and forging a new vision for the future of imaging. Our ultimate goal is to contribute positively to society and enrich people's lives," said Yu Meng.

vivo Announced Winners of VISION+ Mobile PhotoAwards 2024

In recent years, vivo has built a rich imaging culture ecosystem through initiatives like the VISION+ Mobile Photo Awards, co-organized with ZEISS, sparking public creativity and enthusiasm.

vivo announced the winners of the VISION+ Mobile Photo Awards 2024 at the event. Over a span of seven months, the competition received over 600,000 entries worldwide, all captured using vivo smartphones. After rigorous evaluation, a total of 25 award-winning works stood out, including four entries from photographers overseas. Among these are "Happy Together" by Indonesian photographer Maya Nurikawati, "O Shape" by Burmese photographer Aung Chan Thar, "Look Like Painting" by Burmese photographer Win Ei Phu, and "Friendship Goals" by Indian photographer Pradiptamoy Paul.

Among the winning entries across six categories, "A Fleeting Moment in Endless Time" by photographer He Jinyi was honored as the Best Photo of the Year. This photo captures a magnificent moment of a meteor streaking across the sky over a dracaena cinnabari on Socotra Island, a tree species known for its longevity of tens of thousands of years. Using the Handheld Astro feature and long exposure capability of vivo X100 Pro, the photographer precisely captured the dazzling beauty of the night sky.

vivo Unveils Three New Trends in Mobile Imaging

As a pioneer in mobile imaging, vivo has unveiled three key future trends: imaging security, 3D imaging/XR, and health imaging, and shared the company's insights and explorations into the technology industry ecosystem and the future of imaging.

To protect user image data and privacy, as well as to prevent the misuse of image information, vivo is committed to further strengthening its image security technology, establishing a more reliable imaging experience and digital lifestyle for users. In terms of authenticity, vivo consistently innovates in the marking technology for photos and videos. By collaborating with security application and service providers, vivo aims to build a transparent and trustworthy ecosystem for content creation and sharing, achieving the widespread applicability of image security identification. This is also a major direction that vivo and ZEISS will jointly explore.

In terms of 3D imaging and XR technologies, vivo introduces cutting-edge 3D imaging capabilities to vivo X100 Ultra^[1] for the first time, delivering an immersive visual experience. The synchronization of multiple cameras and 3D image processing technology enables the capture of vibrant and lifelike 3D images, which are then stored in a proprietary stereo format. vivo, in partnership with Rokid, pioneers an integrated experience in the industry, blending content creation and consumption. This synergistic relationship empowers the smartphone to capture stunning 3D imagery, while AR glasses elevate the consumption experience, unlocking its full potential. In the field of XR technology, vivo is dedicated to improving the immersive and panoramic viewing experience by projecting distant scenes onto AR glasses or virtual screens. Looking ahead, Yu Meng revealed at the event that vivo will launch MR (Mixed Reality) wearable devices in 2025, further driving the development of spatial imaging.

In the field of smart health, vivo is actively exploring innovative applications of mobile imaging in healthcare services, aiming to develop solutions that are more intelligent and convenient.

Marking a decade of imaging milestones, vivo, from this new starting point, will continue to uphold its user-oriented approach. With a genuine passion for innovation and in collaboration with like-minded partners, vivo will persist in exploring the boundaries of imaging, jointly shaping a visionary blueprint for the future of mobile imaging.

About vivo

vivo is a technology company that creates great products based on a design-driven value, with smart devices and intelligent services as its core. The company aims to build a bridge between humans and the digital world. Through unique creativity, vivo provides users with an increasingly convenient mobile and digital life.

While bringing together and developing the best local talents to deliver excellence, vivo is supported by a network of R&D centers including Shenzhen, Dongguan, Nanjing, Beijing, Hangzhou, Shanghai and Xi'an, focusing on the development of state-of-the-art consumer technologies, including 5G, artificial intelligence, industrial design, photography and other up-and-coming technologies. vivo has also set up an intelligent manufacturing network (including those authorized by vivo), with an annual production capacity of nearly 200 million smartphones. As of now, vivo has branched out its sales network across more than 60 countries and regions, and is winning more than 500 million users worldwide with its superior products and services.

Following the company's core values, which include Benfen*, user-orientation, design-driven value, continuous learning and team spirit. vivo has implemented a sustainable development strategy, with the vision of developing into a healthier, more sustainable world-class corporation.

*"Benfen" is a term describing the attitude on doing the right things and doing things right – which is the ideal description of vivo's mission to create value for society.

SOURCE vivo

VILNIUS, Lithuania, July 27, 2024 /PRNewswire/ -- BingX, a leading cryptocurrency exchange, proudly announces the launch of BingX Pre-Market Trading feature. Utilizing this feature, BingX users can enjoy early access to coins, efficient price discovery, and enhanced liquidity. It also allows for the activation of community trading interests, positioning BingX as a primary market for new assets once they are officially listed. This innovative platform enhancement is set to redefine the landscape of cryptocurrency trading, providing users with unprecedented early access to new digital assets before their official listing, starting with Hamster Kombat  (HMSTR) and Catizen (CATI). This captivating clicker game has garnered a substantial user base interested in the TON Ecosystem built on the Telegram instant messaging app.

Vivien Lin, Chief Product Officer of BingX, expressed her enthusiasm and emphasized the feature's significance for the platform's users. "This new feature represents a major milestone for BingX, providing our users with early access to new coins and the ability to secure advantageous positions before these coins are listed on the spot market. We are dedicated to continually innovating and delivering tools that empower our users to stay ahead in the dynamic cryptocurrency market." said Lin.

Early Opportunities & Real Trades

BingX Pre-Market Trading operates as an over-the-counter (OTC) platform, facilitating genuine peer-to-peer trading of new coins. This feature allows users to acquire coins at optimal prices, secure liquidity in advance, and complete deliveries at mutually agreed-upon times. allowing buyers and sellers to freely choose and create orders based on their preferences and price expectations. Whether acting as a buyer, seller, or both, users can set their desired prices and quantities, ensuring a flexible and user-driven trading environment.

The platform ensures transaction security by freezing the relevant amounts for both buyers and sellers, guaranteeing that every order has solid financial backing. This reduces the risk of failed trades. Sellers can also complete deliveries as soon as they have the coins, locking in their order profits without waiting for the delivery period to end. As a trusted leader in the cryptocurrency trading industry, BingX continues to innovate and deliver features that enhance the trading experience for its global user base. The launch of the Pre-Market Trading feature highlights BingX's commitment to security, reliability, and user empowerment.

About BingX 

Founded in 2018, BingX is a leading crypto exchange, serving over 10 million users worldwide. BingX offers diversified products and services, including spot, derivatives, copy trading, and asset management – all designed for the evolving needs of users, from beginners to professionals. BingX is committed to providing a trustworthy platform that empowers users with innovative tools and features to elevate their trading proficiency. In 2024, BingX proudly became the official crypto exchange partner of Chelsea Football Club, marking an exciting debut in the world of sports.

For more information please visit: https://bingx.com/en/

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/bingx-launches-pre-market-trading-for-early-access-to-new-digital-assets-302207730.html

SOURCE BingX

• The positive CHMP opinion is based on results from the Phase II PHAROS trial,^[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent with that observed in the approved metastatic melanoma indication^[1]
• The European Commission decision for BRAFTOVI^® (encorafenib) + MEKTOVI^® (binimetinib) is expected later this year.

CASTRES, France, July 26, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced today that the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the approval of BRAFTOVI^® (encorafenib) in combination with MEKTOVI^® (binimetinib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF^V600Emutation. The positive opinion will now be submitted to the European Commission (EC) with a decision on EU marketing authorisation (MA) expected later this year.

Eric Ducournau, Chief Executive Officer, Pierre Fabre Laboratories said: "The positive CHMP opinion marks a pivotal step in our commitment to delivering an additional effective targeted treatment option for patients with advanced NSCLC with a BRAF^V600E mutation, who at present have limited treatment options. We look forward to the European Commission's decision to make BRAFTOVI^® + MEKTOVI^® available to non-small cell lung cancer patients in Europe."

The CHMP positive opinion is supported by data from the global, open-label, multicentre, non-randomised Phase II PHAROS trial, which included 98 patients from 56 study centres across 5 countries.^[1]

At primary analysis (cut-off date: September 22, 2022), the primary endpoint of the trial (objective response rate [ORR] determined by independent radiology review [IRR]) was met. The PHAROS trial showed that in patients with advanced NSCLC with a BRAF^V600Emutation, BRAFTOVI^® and MEKTOVI^® provided a meaningful clinical benefit with an ORR of 75% (95% CI: 62, 85) in treatment naïve patients (n=59), with 59% of them maintaining their response for at least 12 months. For those patients who had received prior therapy (n=39), the ORR was 46% (95% CI: 30, 63), with 33% maintaining their response for at least 12 months.^[1]

CONTACT: Laurence MARCHAL laurence.marchal@pierre-fabre.com

SOURCE PIERRE FABRE LABORATORIES

ABU DHABI, UAE, July 26, 2024 /PRNewswire/ -- Warner Bros. World™ Yas Island, Abu Dhabi, the region's largest indoor theme park, is thrilled to announce a groundbreaking extension to its partnership with Etihad Airways, marking a monumental milestone in its history. This exciting collaboration was unveiled to the public on July 25 at a spectacular launch event and will bring the excitement of Warner Bros. World™ to the skies with the launch of the world's first Warner Bros. World™ branded aircraft, taking guests' pre-theme park experience to new heights.

To view the Multimedia News Release, please click: 
https://www.multivu.com/players/uk/9281951-warner-bros-world-yas-island-abu-dhabi-etihad-airways-partnership/

The partnership between Warner Bros. World™ and Etihad Airways represents the largest collaboration for the theme park to date. As part of this captivating initiative, an Etihad Airways aircraft – Boeing 787-10 Dreamliner – has been creatively decorated with iconic Warner Bros. characters. On one side, guests will be greeted by the mischievous antics of iconic Classic Animation characters like the Looney Tunes and Tom and Jerry, while the other side showcases the heroic feats of beloved DC Super Heroes.

All young guests aged up to 10 years old, flying on Etihad Airways longer flights will receive brand new Warner Bros. World™ Kids Packs that are being rolled out across the network this summer. Bursting with creativity, these packs are designed to entertain young travelers with activities that inspire them to draw their favorite superheroes and engage in a variety of fun tasks throughout the flight, ensuring every moment is packed with adventure. Infants will receive a DC Super Hero themed soft blanket, while juniors will receive goodies such as a branded backpack, Super Hero cape, water bottle and activity kit.

Warner Bros. World™ will also debut its exclusively branded, dedicated children's lounge within the Etihad Airways Lounge at Zayed International Airport in Abu Dhabi. This whimsical lounge will transport travelers into the incredible universe of Warner Bros. World™, offering a one-of-a-kind experience that brings the wit of the park to the airport, making every journey as delightful as a visit to the theme park itself.

Expressing his enthusiasm about the partnership, Mohamed Abdalla Al Zaabi, Group CEO of Miral, said: "We are absolutely delighted to partner with Etihad Airways to bring the first-ever Warner Bros. World™ branded aircraft to fans. This collaboration not only expands the customer experience, but also extends the thrill of Warner Bros. World™ beyond our park's walls, creating a super vacation with long lasting unforgettable memories for passengers of all ages."

Adding to this, Antonoaldo Neves, Chief Executive Officer, Etihad Airways, said: "Building on the strong reputation we have built as a family-friendly airline, we're thrilled to take our partnership with Warner Bros. World™ to the next level. Our Looney Tunes and DC Super Hero themed aircraft will take our brands to destinations worldwide promoting one of Abu Dhabi's many attractions. We look forward to welcoming more and more visitors inspired to visit our home, Abu Dhabi, and in particular delighting our Little VIP guests while they journey with us."

View original content:https://www.prnewswire.com/apac/news-releases/warner-bros-world-yas-island-abu-dhabi-soars-to-new-heights-with-etihad-airways-partnership-302207674.html

SOURCE Warner Bros. World™ Yas Island

JAKARTA, Indonesia, July 26, 2024 /PRNewswire/ -- Malaysia Healthcare Travel Council (MHTC) achieved impressive results in numerous fronts in Jakarta! MHTC is the pioneer in organising healthcare expo in Indonesia and the inaugural event was in Semarang in 2012. MHTC has successfully organised two events in Indonesia in the first half of 2024, and the third event in July 2024 held in Jakarta concluded with resounding success with a remarkable attendance of 3,000 visitors resulting in generation of high level of leads and forging of strategic partnerships.

The MHTX Jakarta 2024 was held from 18 to 21 July 2024 at The Forum Atrium, Mall Kelapa Gading 3. It was participated by a record 20 top notch MHTC member hospitals, and for this event both Sabah Tourism Board and Sarawak Tourism board took the pavilion to showcase their state's tourism products.

"We are thrilled by the overwhelming response to MHX Jakarta 2024," said Dato' Syed Md Hasrin Tengku Hussin, Ambassador of Malaysia to Indonesia, who graced the event's opening ceremony. "This expo not only underscores Malaysia's position as a good option of destination for healthcare but also strengthens the bonds between our nations through healthcare excellence."

The event saw extensive of 26 media coverage in Indonesia, highlighting Malaysia's accredited medical treatments in cardiology, oncology, orthopaedics, hepatology, IVF, gastroenterology, ophthalmology, and internal medicine. attraction, reflecting Indonesian patients' growing trust in Malaysia's healthcare expertise.

The first quarter of 2024 saw a 24% increase in Indonesian health tourism volume. It reflects the trust and confidence that Indonesian patients have in Malaysia as a trusted and reliable destination for their medical needs. For that, MHTC aims to continue enhancing its offerings, focusing on both curative and preventive care.

MHX Jakarta July 2024 featured promotions and interactive activities supported by partners Bank Muamalat Indonesia and JavaMifi, offering attendees exciting opportunities to win prizes while learning about Malaysia's healthcare advantages. From quality healthcare facilities accredited globally to affordable treatment costs and seamless patient experiences, Malaysia would continue to be the preferred option for Indonesian health tourists.

"The success of MHX Jakarta July 2024 would not have been possible without the dedication of our member hospitals and partners," remarked the MHTC VP MarComms Mr. Lokman Izam. "Their commitment to excellence and innovation has set new benchmarks in healthcare accessibility for our Indonesian visitors."

As MHX Jakarta July 2024 concluded on a high note, we are moving to Surabaya, where MHTC plans its next healthcare expo. Stay tuned for further details as we continue to bring Malaysia's award-winning healthcare closer to healthcare patients in Indonesia and beyond.

#ExperienceMalaysiaHealthcare #MHExpoJakarta2024 #LebihDekatLebihTerjangkau

Malaysia Healthcare Travel Council (MHTC), founded in 2009 and operating under the purview of Ministry of Health (MOH) Malaysia, is tasked with developing and nurturing the "Malaysia Healthcare" brand. MHTC enhances, coordinates, and promotes Malaysia's healthcare travel industry by fostering industry collaborations and establishing valuable public-private partnerships both domestically and internationally. Working with over 92 private hospitals across Malaysia, MHTC aims to elevate the healthcare travel industry through an active ecosystem, a robust "Malaysia Healthcare" brand, and strategic market initiatives. The "Malaysia Healthcare" brand aspires to position Malaysia as the premier global healthcare destination. As a significant export service, Malaysia's healthcare travel industry plays a vital role in the nation's economy.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mhx-jakarta-18-21-july-2024-wrapped-up-with-record-turnout-high-leads-generation-and-strategic-partnerships-302207549.html

SOURCE Malaysia Healthcare Travel Council

QINGDAO, China, July 26, 2024 /PRNewswire/ -- As the world's biggest sporting occasion gets underway, Hisense, a global leader in consumer electronics and appliances is igniting sporting passions direct from Paris with its 'Big Game, Big Screen' campaign.

Highlight of Hisense's ongoing global promotional campaign is the awe-inspiring 100-inch U7 ULED TV, transforming any living room into the ultimate viewing arena and bringing all the excitement of elite athletic endeavor into the home on the big screen, thanks to ULED TV 100-inch display technology.

Hisense ranked global No.1 for 100-inch TVs in both 2023 and Q1 2024, and is on track to winning-over dedicated sports fans in embracing the 100-inch TV era with the industry's largest size of LED TVs.

Settle in to enjoy all the world's best athletic and sports action this August with 100-inch immersive viewing experiences across a wide-range of Hisense TV product lines offering the very latest in picture and audio technologies. 

A podium-winning stand out TV in the Hisense product series is the U7 Mini-LED ULED which features a native 120Hz refresh rate and AI Sports Mode that removes "noises" using a dynamic algorithm tailored to moving objects, creating vibrant, crystal-clear sports action viewing.

Hisense state-of-the-art LED backlight control and color management technologies ensure the brightest sharpest pictures, while the Hisense Hi-View Engine elevates and enhances overall picture quality with authentic color, brilliant contrast, clear motion, and distinct details.

Designed to ensure an unparalleled immersive experience the U7 ULED TV will transform your sports viewing to gold-medal standards. Thanks to Hisense and 100-inch viewing, major sporting experiences will never be quite the same.

About Hisense

Hisense is a leading global home appliance and consumer electronics brand and official partner of the UEFA EURO 2024™. According to Omdia, Hisense ranked No. 2 globally for TV shipments and No. 1 in 100" TVs in both 2023 and Q1 2024. The company has expanded quickly to operate in more than 160 countries and specializes in multi-media goods, home appliances, and intelligent IT information.

SOURCE Hisense

BEIJING, July 26, 2024 /PRNewswire/ -- Boasting rich wetland resources, Harbin City in northeast China's Heilongjiang Province has become a popular tourism destination in summer days this year.

Since the start of July, the search volume for "wetlands" in Harbin on Chinese e-commerce platform Meituan has increased 23 percent year on year, with the number of related travel tips surging 151 percent year on year, according to data from Meituan.

Recently, the number of tourist visits to the Hulan River estuary wetland park has significantly increased, reaching about 5,000 on weekends, according to Zhang Huan, the park's operation manager.

The park gives priority to wetland ecosystem conservation. Meanwhile, it provides diversified services for visitors to do exercises and enjoy recreational activities.

As one of the Chinese cities certified as "International Wetland Cities", Harbin has been stepping up wetland conservation and restoration efforts.

It has implemented the medium- and long-term wetland protection plan (2019-2035), and rolled out wetland protection measures, a work plan for wetland ecological conservation and restoration, as well as an implementation plan for the enforcement of the national wetland protection law, securing law-based protection endeavors aiming to enhance the quality of wetlands, according to Xing Guangyou, director of wetlands and natural reserves management division of Harbin municipal forestry and grassland administration.

Wetland parks have established relevant management mechanisms. For example, Alejin Island national wetland park has introduced wetland protection management system, wildlife protection and rescue system, water quality monitoring and management system and so on. The national level wetland park covers an area of 419 hectares, of which 71.1 percent are wetlands.

Through years of efforts, Harbin has restored more than 3,000 hectares of wetlands, and reverted cultivated land into 685 hectares of wetlands.

Harbin's achievements in wetland protection have earned good returns. Approximately one million tourist visits are made to Harbin each year, creating a total income hitting tens of billions of yuan for the city.

See the original link: https://en.imsilkroad.com/p/341314.html  

SOURCE Xinhua Silk Road

• Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international approval of a China domestic anti-PD-L1 mAb.
• The European Commission (EC) approval is based on the results of GEMSTONE-302 Phase 3 trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival and overall survival in treatment-naive patients with metastatic NSCLC.
• CStone has entered into a strategic commercialization partnership with Ewopharma for sugemalimab in Central & Eastern Europe and Switzerland.
• Discussions for commercial partnerships in including Western Europe, Latin America, the Middle East, Southeast Asia, etc., are progressing well and are expected to conclude soon.
• CStone is actively preparing to submit additional Marketing Authorization Applications (MAAs) to the European Medicines Agency (EMA) for new indications, including Stage III NSCLC, first-line Gastric Cancer, first-line Esophageal Cancer, and relapsed/refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL).

SUZHOU, China, July 26, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the European Commission (EC) has approved sugemalimab (Brand name: Cejemly^®) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small-cell lung cancer (NSCLC) with no sensitizing EGFR mutations, or ALK, ROS1 or RET genomic tumour aberrations. Sugemalimab has become the first anti-PD-L1 monoclonal antibody (mAb) approved in Europe in combination with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC, making CStone the first innovative biopharmaceutical company to successfully bring a China domestic anti-PD-L1 mAb to the international market.

The EC approval is primarily based on the results of the GEMSTONE-302, a multicenter, randomized, double-blind phase 3 study. The study demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival and overall survival compared to placebo combined with chemotherapy in treatment-naïve patients with metastatic NSCLC. The study results have been published in The Lancet Oncology and Nature Cancer, and have been presented at multiple international academic conferences. Additionally, long-term treatment and survival data from the GEMSTONE-302 study will be presented in a poster session (#1318P) at the 2024 ESMO Annual Meeting.

Dr. Jason Yang, CEO, President of R&D and Executive Director of the Board at CStone, said, "We are extremely excited by today's announcement, which represents a major milestone in CStone's journey towards becoming a leading global company dedicated to eradicating cancer. Sugemalimab has not only become CStone's first independently-developed product to receive overseas marketing authorization but it is also the world's first anti-PD-L1 mAb to receive regulatory approval in Europe in combination with chemotherapy as first-line treatment for both squamous and non-squamous NSCLC. This achievement reflects the international regulatory authorities' recognition of our high-quality R&D and manufacturing standards, and it infuses new momentum into our globalization strategy. We are humbled by level of interest in sugemalimab commercial partnership from companies around the world which only signifies the large unmet need in this class for newer and better drugs. We are actively engaging with potential partners in Western Europe, Latin America, the Middle East and Africa, Southeast Asia, and Canada and we expect to announce the completion of these deals soon."

Dr. Yang recalled, " In early May 2023, CStone regained the development and commercialization rights for sugemalimab outside Greater China. Since then, the entire company acted swiftly, with all departments working in coordination to thoroughly review regulatory and submission documents, assess their completeness, perform gap analyses, screened and replaced numerous suppliers, and completed the applicant transfer and submission dossier updates. Within just over a month of fully taking over the MAA, the EMA issued a critical Day 120 List containing 194 outstanding questions. After analyzing a vast amount of data, our team submitted a detailed response to the EMA within the required timeframe. By Day 180, nearly 90% of the responses issues has accepted by EMA's Reviewers resolved, and the remaining ones were further clarified and eventually agreed by the EMA. During the review period, we also successfully passed the EMA's routine GMP inspection of the manufacturing plant, and GCP inspections of two study centers and a CRO, which lasted a total of three weeks. Subsequently, at the end of May this year, we received a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP) recommending approval of sugemalimab. I truly believe that this journey, marked by numerous challenges, reflects the CStone team's resilience and innovative spirit."

Dr. Jason Yang emphasized, "The international approval and commercialization of sugemalimab mark a significant milestone in CStone's Pipeline 1.0 strategy, demonstrating our success in developing best-in-class immuno-oncology drugs for monotherapy and as a foundation for combination therapies. In Pipeline 2.0, we have global rights for a range of highly promising candidates, either in international multicenter clinical trials or approaching the clinical stage, with the potential to be first-in-class or best-in-class. Additionally, we are actively exploring the combination of sugemalimab with other treatment modalities, such as antibody-drug conjugates (ADCs) and bi-/tri-specific antibodies, to enhance its clinical value as a backbone of cancer immunotherapy."

Dr. Yang added, "The seven-year journey of sugemalimab to becoming a first-line treatment for NSCLC in Europe and other cancers in China is a testament to the extensive expertise of numerous Chinese oncology specialists. It also reflects the dedication of patients who participated in sugemalimab clinical trials and the relentless efforts of our R&D team over the years. The remarkable results of the GEMSTONE-302 study provide definitive scientific evidence supporting the use of sugemalimab in combination with chemotherapy as a first-line standard therapy for Stage IV NSCLC. We are honored and humbled that this 'Chinese innovative solution' may significantly improve outcomes for lung cancer patients worldwide, offering both longer survival and a better quality of life."

Meanwhile, CStone is actively preparing to submit multiple Marketing Authorization Applications (MAAs) for additional indications, including Stage III NSCLC, first-line Gastric Cancer, first-line Esophageal Cancer, and relapsed/refractory extranodal natural killer/T-cell lymphoma (r/r ENKTL).

About Lung Cancer

In 2020, lung cancer was the third most diagnosed cancer in Europe and the leading cause of cancer-related mortality, accounting for one fifth of cancer deaths.^[1] Approximately fifty to seventy percent of lung cancer cases in Europe are diagnosed in Stage IV. ^[2] Globally, it is estimated that NSCLC accounts for approximately 85% of all lung cancers.^[3]

About Sugemalimab

The anti-PD-L1 monoclonal antibody sugemalimab was developed by CStone using OmniRat^® transgenic animal platform, which allows creation of fully human antibodies in one step. Sugemalimab is a fully human, full-length anti-PD-L1 immunoglobulin G4 (IgG4) monoclonal antibody, which may reduce the risk of immunogenicity and toxicity for patients, a unique advantage over similar drugs. Sugemalimab's unique molecular design enables a dual mechanism of action that not only blocks PD-1/PD-L1 interaction, but also induces antibody dependent cellular phagocytosis (ADCP) by cross-linking PD-L1 expressing tumor cells with tumor associated macrophages (TAMs) without harming Effector T-cells. This differentiation has resulted in potentially best-in-class efficacy/safety across a variety of tumor types.

The National Medical Products Administration (NMPA) of China has approved sugemalimab for five indications:

• In combination with chemotherapy as first-line treatment of patients with metastatic squamous and non-squamous NSCLC;
• For the treatment of patients with unresectable Stage III NSCLC whose disease has not progressed following concurrent or sequential platinum-based chemoradiotherapy;
• For the treatment of patients with relapsed or refractory extranodal NK/T-cell lymphoma;
• In combination with fluorouracil and platinum-based chemotherapy as first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC; and
• In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5).

The European Commission (EC) has approved sugemalimab (brand name: Cejemly^®) in combination with chemotherapy for the first-line treatment of patients with metastatic NSCLC.

The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has accepted the marketing authorization application for sugemalimab in combination with chemotherapy for first-line treatment of metastatic NSCLC. The application is currently under review.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patient's unmet medical needs in China and globally, the company has made significant strides since its inception. To date, the company has successfully launched four innovative drugs and secured approvals for 15 new drug applications (NDAs) covering 9 indications. The company's pipeline is balanced by 12 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization.

For more information about CStone, please visit www.cstonepharma.com.

IR contact: ir@cstonepharma.com

PR contact: pr@cstonepharma.com

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals.

[1] Dyba T, et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur J Cancer. 2021;157:308-347.
[2] van Meerbeeck, J. et al. Lung cancer screening in Europe: where are we in 2021? Transl Lung Cancer Res,2021;10(5) 2407-2417.
[3] Zhang, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7:78985-78993.

View original content:https://www.prnewswire.com/apac/news-releases/cstone-announces-european-commission-approval-of-sugemalimab-cejemly-as-first-line-treatment-for-non-small-cell-lung-cancer-302207511.html

SOURCE CStone